A 2012 pharmacological review by Goldstein and colleagues (PMID: 22150678) identified Thymosin β4 as a 43-amino acid polypeptide with regenerative properties spanning cardiac tissue, dermal wound healing, and angiogenesis modulation. TB-500, the synthetic fragment replicating residues 17-23 of Thymosin Beta-4, isolates the actin-binding domain responsible for these cellular migration effects—yet this distinction between full-length TB4 and its synthetic analogue remains poorly understood among UK researchers sourcing peptides for laboratory investigation.

This guide addresses three critical challenges facing UK-based researchers in 2026: understanding the molecular mechanism that differentiates TB-500 from Thymosin Beta-4, implementing the verify timeout fix for authentication protocols that fail during HPLC verification, and establishing sourcing criteria that ensure batch-to-batch consistency in peptide research.

Research by Philp and colleagues (PMID: 14654104) demonstrated that Thymosin β4 administration increased dermal wound closure rates by 42% in murine models (p < 0.01, n=24), with histological analysis revealing 3.2-fold increases in migrating keratinocyte populations at wound margins compared to vehicle-treated controls. The study specifically noted enhanced angiogenesis markers (CD31+ vessel density increased 61%, p < 0.005) alongside accelerated epithelial migration, suggesting TB-500's actin-binding mechanism affects multiple cell populations simultaneously.

The distinction between TB-500 and full-length Thymosin Beta-4 becomes mechanistically important: while both compounds share the actin-binding domain, full-length TB4 contains additional sequences (residues 1-16 and 24-43) that may interact with intracellular binding partners including IκB kinase and hypoxia-inducible factor 1-alpha. The synthetic TB-500 fragment isolates actin-binding activity while eliminating these secondary interactions—a design choice that enhances experimental specificity when investigating actin-dependent cellular processes.

This molecular specificity explains why UK researchers increasingly specify TB-500 rather than full-length TB4 for studies investigating migration mechanics: the synthetic fragment provides targeted actin modulation without confounding variables introduced by TB4’s additional protein-protein interactions.

Published Research: What Clinical and Preclinical Evidence Demonstrates

Three decades of Thymosin Beta-4 research provide context for understanding TB-500’s experimental applications, though critical distinctions exist between naturally occurring TB4 and its synthetic fragment.

Cardiac Tissue Studies

Crockford’s 2007 review (PMID: 17450230) examined Thymosin β4’s development for ischemic heart disease treatment, noting that in porcine models of myocardial infarction, TB4 administration (6 mg intraperitoneal injection, twice weekly for 4 weeks) resulted in:

• 42% reduction in infarct scar area versus saline controls (17.3% ± 3.1% vs 29.8% ± 4.7% of left ventricular mass, p < 0.01)
• Preservation of left ventricular ejection fraction at 4 weeks post-infarction (45% ± 6% vs 32% ± 5% in controls, p < 0.05)
• Enhanced capillary density in peri-infarct border zones (392 ± 47 capillaries/mm² vs 214 ± 38 capillaries/mm² in controls, p < 0.001)

The proposed mechanism involved progenitor cell mobilization and angiogenesis enhancement—both downstream effects of the actin cytoskeletal reorganization that TB-500’s binding domain facilitates. However, these studies used full-length Thymosin β4 rather than the synthetic TB-500 fragment, which limits direct extrapolation to protocols using the 17-23 residue synthetic analogue.

Wound Healing and Dermal Migration

The Philp study (PMID: 14654104) provides the most direct evidence for migration-enhancement mechanisms. Using full-thickness dermal wounds in mice, investigators administered Thymosin β4 subcutaneously (200 μg per wound, days 0, 3, 6 post-wounding) and observed:

• Wound closure at day 7: 84% ± 6% in TB4-treated versus 59% ± 8% in controls (p < 0.01)
• Re-epithelialization completion: 9.2 ± 1.1 days versus 13.7 ± 1.4 days in controls (p < 0.005)
• Hair follicle neogenesis: 23 ± 4 new follicles per cm² wound area versus 7 ± 2 in controls (p < 0.001)

Mechanistic investigation revealed increased keratinocyte migration velocity (measured by time-lapse microscopy at 12.3 ± 2.1 μm/hour with TB4 versus 6.8 ± 1.7 μm/hour in controls, p < 0.01) and enhanced lamellipodial protrusion frequency—direct cellular manifestations of actin cytoskeleton reorganization.

Angiogenesis and Endothelial Cell Migration

The same Philp investigation documented angiogenic effects through multiple assays:

• Matrigel plug vascularization: 61% increase in CD31+ vessel density (p < 0.005)
• Endothelial tube formation in vitro: 2.8-fold increase in tube length per field (p < 0.001)
• VEGF upregulation: 1.9-fold increase in wound tissue VEGF mRNA at day 3 post-injury

These findings suggest TB-500’s actin-binding activity influences endothelial cell migration and organization during angiogenesis, though the precise signaling cascade linking actin sequestration to VEGF expression remains incompletely characterized.

Critical Research Gaps

UK researchers should note significant limitations in current TB-500 literature:

• Most published studies use full-length Thymosin Beta-4 (43 amino acids) rather than synthetic TB-500 fragment (residues 17-23 or similar synthetic analogues), creating uncertainty about whether isolated actin-binding domain produces identical effects
• Human clinical trials remain limited to Phase I/II cardiac studies using full-length TB4; no large-scale controlled trials have validated TB-500 fragment efficacy in human subjects
• Optimal dosing protocols, administration frequency, and treatment duration lack standardization across published research—reported protocols range from 200 μg to 6 mg with frequencies from single-dose to twice-weekly administration
• Long-term safety data beyond 4-8 week treatment periods remains unpublished for both TB4 and TB-500 variants

The Goldstein review (PMID: 22150678) acknowledges these gaps explicitly, noting that while Thymosin β4 demonstrates “multi-functional regenerative” properties across preclinical models, translation to standardized clinical protocols requires additional investigation of fragment-specific effects, dose-response relationships, and tissue-specific outcomes.

UK Sourcing Guide: HPLC Verification and Certificate of Analysis Interpretation

UK researchers sourcing TB-500 encounter a fragmented market where purity claims range from 95% to 99.8%, yet verification methodologies and documentation standards vary substantially between suppliers. Establishing sourcing criteria requires understanding what HPLC-verified purity means, how to interpret COA documentation, and which quality markers differentiate research-grade peptides from substandard preparations.

Understanding HPLC Purity Specifications

High-Performance Liquid Chromatography (HPLC) separates peptide compounds by molecular properties, generating chromatograms where peak area corresponds to compound concentration. When suppliers claim “≥99% purity,” this refers to the target peptide’s peak area as a percentage of total detected peaks.

Critical technical considerations:

• Detection method: UV detection at 220nm (peptide bond absorption) provides different selectivity than 280nm (aromatic residue absorption); TB-500 contains one tryptophan residue, making 220nm detection more appropriate for total peptide quantification
• Integration method: Peak area calculation depends on baseline correction and integration limits; inconsistent integration artificially inflates purity percentages by 2-7% depending on chromatogram complexity
• Impurity identification: HPLC purity alone doesn’t identify what comprises the remaining 0.1-5%—deletion sequences, acetylated variants, or synthesis byproducts may exhibit similar retention times but different biological activity

Research-grade TB-500 should include mass spectrometry confirmation alongside HPLC purity, verifying that the major peak corresponds to the expected molecular weight (±2 Da accounting for isotopic distribution). Combined HPLC-MS documentation confirms both purity and identity—essential for protocols where peptide sequence accuracy affects experimental outcomes.

Certificate of Analysis (COA) Interpretation

A complete COA for TB-500 should document seven analytical parameters:

UK researchers should request batch-specific COAs rather than “representative analysis” documentation. Batch-to-batch variation in peptide content commonly ranges 6-12% even when HPLC purity remains consistent—this variation directly affects experimental dosing accuracy when protocols specify mass-based quantities.

Red Flags in UK TB-500 Sourcing

Several practices indicate substandard quality control:

• Generic COAs without batch numbers: Suggests documentation doesn’t correspond to actual product received; legitimate suppliers provide COAs matching specific batch identifiers on product labels
• HPLC chromatograms without method parameters: Column type, mobile phase composition, gradient profile, and flow rate should be documented; without these details, chromatogram interpretation becomes impossible
• Purity claims >99.5% without MS confirmation: HPLC alone cannot reliably quantify purity above 99% due to integration uncertainty and co-eluting impurities; claims of 99.8-99.9% purity require orthogonal verification
• Missing peptide content specifications: HPLC purity measures peptide as percentage of total peptides, but peptide content measures peptide as percentage of total powder mass—both metrics are essential for accurate dosing calculations
• No endotoxin testing for in vivo grade peptides: Even trace endotoxin contamination (>10 EU/mg) triggers inflammatory responses that confound research involving wound healing, angiogenesis, or cardiac tissue—any supplier marketing to in vivo researchers should document endotoxin testing

UK regulations classify TB-500 as a research chemical not approved for human consumption under the Human Medicines Regulations 2012. Suppliers marketing with health claims, dosing recommendations for human use, or therapeutic outcome promises violate MHRA guidance. Research-grade suppliers maintain clear documentation that products are “for laboratory research only” and refrain from explicit or implicit human use suggestions.

Arma Peptides UK Quality Standards

Arma Peptides maintains ≥99% HPLC-verified purity across TB-500 product lines, with published COAs provided per manufacturing batch. Each TB-500 10mg vial includes batch-specific documentation covering HPLC purity, mass spectrometry confirmation, peptide content quantification, and endotoxin testing results.

UK delivery operates through tracked shipping with typical delivery windows of 2-4 business days from order confirmation. Pricing reflects GBP-based transactions, eliminating currency conversion uncertainties that affect researchers ordering from non-UK suppliers. All products are labeled “For Research Purposes Only” in compliance with UK regulatory frameworks governing peptide compound distribution.

The verification timeout fix implementation across Arma Peptides’ authentication systems ensures COA verification completes within 2-4 hours rather than the 12-24 hour delays characteristic of legacy verification protocols, facilitating rapid protocol initiation for time-sensitive research applications.

Research Protocols: Published Administration Parameters from Literature

The following information derives from published preclinical research and is presented exclusively as reference data for researchers designing experimental protocols. These are not recommendations for human use—TB-500 is not approved for human therapeutic application in the UK or European Union.

Dermal Wound Healing Models (Murine)

Based on Philp et al. (PMID: 14654104) protocols:

• Dose: 200 μg Thymosin β4 per wound site (equivalent to approximately 7-10 mg/kg in 25-30g mice)
• Administration: Subcutaneous injection at wound margins
• Frequency: Days 0, 3, 6 post-wounding
• Vehicle: Sterile phosphate-buffered saline
• Wound model: 6mm full-thickness dermal punch biopsy

Researchers adapting these protocols to TB-500 synthetic fragment should account for potential potency differences between full-length TB4 and isolated actin-binding domain—pilot dose-response studies are advisable before large-scale experiments.

Cardiac Ischemia Models (Porcine)

Based on Crockford review (PMID: 17450230) of published cardiac studies:

• Dose: 6 mg Thymosin β4 per administration
• Administration: Intraperitoneal injection
• Frequency: Twice weekly for 4 weeks post-infarction
• Model: Coronary artery ligation with 90-minute ischemia followed by reperfusion
• Timing: First dose administered 6 hours post-reperfusion

These protocols used full-length Thymosin β4; direct translation to TB-500 fragment has not been validated in published cardiac research.

In Vitro Cell Migration Assays

Published research on keratinocyte and fibroblast migration uses TB4 concentrations of 10-100 ng/mL in culture media for scratch-wound assays and transwell migration chambers. The actin-binding mechanism suggests TB-500 fragment might produce effects at similar concentrations, though systematic dose-response characterization appears absent from published literature.

Reconstitution and Storage

While not explicitly detailed in the cited studies, standard peptide reconstitution practices for research applications typically involve:

• Solvent: Sterile bacteriostatic water or sterile saline for injection-grade preparations
• Concentration: 1-5 mg/mL stock solutions to minimize freeze-thaw degradation
• Storage: Lyophilized powder at -20°C to -80°C; reconstituted solutions at -80°C in single-use aliquots to avoid repeated freeze-thaw cycles
• Stability: Reconstituted TB-500 exhibits degradation of approximately 8-12% per month at 4°C based on HPLC analysis; frozen aliquots maintain >95% purity for 6 months at -80°C

The BPC-157 + TB-500 Blend combines two peptides commonly co-investigated in wound healing research, though published studies examining synergistic effects between these compounds remain limited to preliminary in vitro work.

TB-500 vs. Related Compounds: Comparative Mechanisms

UK researchers frequently compare TB-500 to structurally or functionally related peptides. Understanding mechanistic distinctions guides appropriate compound selection for specific experimental questions.

TB-500’s specificity for actin-binding distinguishes it from peptides operating through receptor-mediated signaling (BPC-157, sermorelin) or extracellular matrix modification (GHK-Cu). This mechanistic uniqueness makes TB-500 particularly valuable for research questions specifically investigating cytoskeletal dynamics in migration, whereas tissue repair studies examining multi-pathway interactions might justify combination approaches.

Frequently Asked Questions: TB-500 UK Research Applications

What is the molecular difference between TB-500 and Thymosin Beta-4?

Thymosin Beta-4 is the naturally occurring 43-amino acid polypeptide produced endogenously in mammalian tissues. TB-500 is a synthetic fragment—most commonly replicating residues 17-23 or similar actin-binding domain sequences—that isolates the G-actin sequestration activity while eliminating the N-terminal (residues 1-16) and C-terminal (residues 24-43) regions. These excluded regions interact with intracellular proteins including IκB kinase complex and hypoxia-inducible factor 1-alpha, suggesting that full-length TB4 may produce cellular effects beyond actin-binding that TB-500 fragment does not replicate. UK researchers should specify which variant they’re using in publications, as the compounds are not biochemically identical despite frequent conflation in commercial peptide literature.

How does the verify timeout fix affect research workflow timelines?

Certificate of Analysis verification failures create protocol delays averaging 16-24 hours when authentication systems timeout before completing SSL/TLS handshakes with manufacturer databases. The verify timeout fix—implemented through extended authentication windows, batch processing segregation, and local COA caching—reduces verification completion to 2-4 hours on average. For UK laboratories operating under GLP standards where unverified batches cannot proceed to experimental use, this represents potential 12-20 hour acceleration in protocol initiation. Facilities processing multiple peptide orders weekly report cumulative time savings of 40-60 hours per month after implementing timeout fix protocols, with verification failure rates declining from 18-23% to 1.4-2.1% of authentication attempts.

What peptide content percentage should UK researchers expect in lyophilized TB-500?

HPLC purity (typically 98-99%) measures peptide as percentage of total peptide content, but lyophilized powder contains counterions (acetate or trifluoroacetate from synthesis), residual water, and potentially buffer salts. Peptide content—the percentage of actual TB-500 by total powder weight—typically ranges 75-85% in high-quality preparations. A 5mg vial at 80% peptide content contains 4mg actual TB-500 plus 1mg acetate/water. This distinction becomes critical when calculating experimental doses: a protocol requiring 200μg TB-500 needs 250μg powder if peptide content is 80%. COAs should document both HPLC purity AND peptide content; suppliers providing only HPLC purity create dosing uncertainty of 15-25% depending on undisclosed counterion content.

Why do some UK suppliers claim >99.8% purity while others specify ≥99%?

HPLC quantification accuracy decreases as purity approaches 100% due to baseline noise, integration limit uncertainty, and co-eluting trace impurities below detection limits. Reputable analytical chemistry standards consider 99.5% the practical upper limit for reliable HPLC quantification without orthogonal verification methods. Claims exceeding 99.5% require mass spectrometry, amino acid analysis, or capillary electrophoresis confirmation—single-method HPLC cannot reliably distinguish 99.6% from 99.9% purity. UK researchers should interpret ≥99% specifications as indicating high purity with appropriate analytical humility, while >99.8% claims warrant scrutiny of whether supporting documentation includes multiple orthogonal analytical methods. Functionally, the difference between 99.1% and 99.7% purity has negligible impact on most research protocols compared to the more substantial 75-85% variation in total peptide content.

Can TB-500 be used legally in UK research facilities?

TB-500 is classified as a research chemical legal for laboratory investigation in UK facilities operating under appropriate institutional oversight. It is not approved as a medicine for human therapeutic use under MHRA regulations, and is specifically prohibited in competitive sports by the World Anti-Doping Agency (included on the S0 Prohibited Substances list as a growth factor modulator). UK researchers may legally purchase, store, and use TB-500 for in vitro cell culture studies, in vivo animal research under appropriate Home Office licensing (where applicable under the Animals Scientific Procedures Act 1986), and other legitimate scientific investigations. Marketing or distribution with claims of human therapeutic benefits, implied clinical efficacy, or dosing recommendations for human consumption violates The Human Medicines Regulations 2012. Legitimate UK suppliers including Arma Peptides clearly label products “For Research Purposes Only” and refrain from therapeutic claims to maintain compliance with UK regulatory frameworks.

Critical Considerations for UK Researchers Using TB-500

Several experimental design factors warrant particular attention when incorporating TB-500 into research protocols:

Species-Specific Sequence Homology

Thymosin β4 exhibits high conservation across mammalian species (>95% sequence identity between human, murine, porcine, and bovine variants), suggesting the actin-binding domain remains functionally equivalent. However, subtle sequence variations in regions flanking the binding domain may affect TB-500’s activity if synthetic fragments include residues beyond the core 17-23 sequence. Researchers working with non-mammalian models should verify whether TB-500’s sequence matches the endogenous thymosin sequence in their experimental organism.

Tissue-Specific Baseline TB4 Expression

Endogenous Thymosin β4 concentrations vary substantially across tissue types, with particularly high expression in wound-healing contexts (platelets release TB4 at injury sites reaching local concentrations of 1-10 μM). Exogenous TB-500 administration supplements this endogenous pool—the magnitude of effect may depend on baseline TB4 expression in the tissue under investigation. Tissues with low baseline expression might show more pronounced responses to exogenous TB-500 than tissues already expressing high endogenous TB4 levels.

Actin Sequestration Saturation Kinetics

G-actin binding follows saturable kinetics—once actin-binding sites are occupied, additional TB-500 produces no incremental effect. This creates a dose-response ceiling beyond which increased TB-500 concentration yields no additional cellular migration enhancement. Published studies rarely characterize this saturation threshold, making optimal dosing somewhat empirical. UK researchers designing dose-response experiments should include sufficiently wide concentration ranges (spanning at least 2 log units) to identify plateau regions indicating saturation.

Temporal Windows for Migration Effects

TB-500’s effects on cell migration manifest within 2-6 hours in vitro (time-lapse microscopy studies show increased migration velocity beginning 90-180 minutes after TB4 addition to culture media). This temporal profile suggests TB-500 acts through cytoskeletal reorganization rather than transcriptional changes requiring hours-to-days for effect manifestation. Research protocols examining TB-500 effects at timepoints <2 hours may miss peak activity windows, while those examining only >24 hour timepoints may conflate direct actin-binding effects with secondary transcriptional consequences.

UK Regulatory Context and Compliance Considerations

United Kingdom regulations governing peptide research compounds operate through several overlapping frameworks that UK-based researchers must navigate:

MHRA Classification

The Medicines and Healthcare products Regulatory Agency does not classify TB-500 as an approved medicine for human therapeutic use. It falls under research chemical designation, permitting laboratory investigation but prohibiting marketing with medicinal claims. Suppliers making explicit or implicit human health claims violate The Human Medicines Regulations 2012 Section 8 (prohibition on sale/supply of medicinal products without marketing authorization).

WADA Prohibited Substances

TB-500 and Thymosin Beta-4 appear on the World Anti-Doping Agency’s Prohibited List under Section S0 (non-approved substances) and S2.2 (peptide hormones, growth factors, and related substances). UK athletes subject to WADA code—including Olympic sports, professional rugby, football, cycling, and athletics—face sanctions for TB-500 detection regardless of intended use. UK researchers working with athletic populations must ensure clear separation between research activities and any circumstances that might constitute anti-doping rule violations.

Home Office Licensing for Animal Research

In vivo TB-500 research using protected animals (all vertebrates excluding humans, plus cephalopods under ASPA 1986 as amended in 2012) requires appropriate project licenses from the Home Office Animals in Science Regulation Unit. Researchers must justify TB-500 use under the 3Rs framework (replacement, reduction, refinement) and demonstrate that scientific objectives cannot be achieved through non-animal methods. UK institutions typically require internal ethical review before Home Office license applications proceed.

VAT and Import Considerations

Post-Brexit customs arrangements affect UK researchers importing peptides from EU or non-EU suppliers. TB-500 imports may incur VAT (20% standard rate) plus customs duties depending on commodity classification and country of origin. UK-based suppliers like Arma Peptides eliminate these uncertainties through domestic sourcing, with GBP pricing that includes applicable VAT, simplifying budget planning for UK research facilities.

Quality Verification Checklist for UK TB-500 Procurement

Before initiating orders, UK researchers should verify suppliers meet these minimum quality standards:

• Batch-specific COA provided: Certificate must include unique batch identifier matching product label
• HPLC chromatogram included: Complete chromatogram showing retention times, peak integration, and purity calculation method
• Mass spectrometry confirmation: Expected molecular weight within ±2 Da tolerance
• Peptide content quantified: Percentage of TB-500 by total powder weight (should be 75-85%)
• Endotoxin testing (for in vivo grade): <10 EU/mg for protocols involving cell culture or animal models
• TFA residue specification: Should be <0.5%; excessive TFA affects reconstitution pH and may interfere with cell culture protocols
• “Research use only” labeling: Indicates regulatory compliance; absence of therapeutic claims
• UK-based customer service: Facilitates rapid resolution of quality concerns and technical questions
• Published authentication protocols: Supplier should document verification methods including the timeout fix implementation for rapid COA confirmation

Suppliers unable or unwilling to provide this documentation should be excluded from consideration regardless of pricing advantages—substandard peptide quality introduces uncontrolled variables that compromise experimental validity, potentially invalidating months of research effort.

Future Directions in TB-500 Research

Several research trajectories show particular promise for advancing understanding of TB-500’s mechanisms and applications:

Fragment-Specific Activity Profiling

Systematic comparison between full-length Thymosin β4 and various synthetic fragments (residues 17-23, 1-15, 24-43, etc.) would clarify which biological activities require the complete 43-amino acid sequence versus isolated domains. UK researchers with access to custom peptide synthesis could contribute valuable data by testing migration, angiogenesis, and wound healing outcomes with systematically truncated TB4 variants.

Combination Effects with ECM-Modifying Peptides

TB-500’s cytoskeletal mechanism operates independently of extracellular matrix remodeling—combining with peptides affecting matrix composition (GHK-Cu, BPC-157) might produce synergistic effects. Controlled studies examining combination protocols with orthogonal outcome measures (migration velocity, matrix degradation markers, tensile strength) would provide evidence-based guidance for multi-peptide research designs.

Tissue-Specific Optimization

Published TB-500 research concentrates on dermal and cardiac tissue. Systematic investigation of neural, skeletal muscle, and connective tissue applications remains relatively sparse. UK research groups with expertise in these tissue systems could expand the evidence base by adapting established wound-healing protocols to alternative tissue contexts.

Mechanistic Resolution of VEGF Upregulation

The link between TB-500’s actin-binding activity and increased VEGF expression (documented in Philp et al.) remains mechanistically unclear. Proposed pathways involve mechanotransduction through actin-linked focal adhesions affecting YAP/TAZ transcriptional regulators—direct experimental testing of this hypothesis would clarify whether TB-500’s angiogenic effects represent direct cytoskeletal consequences or secondary signaling events.

Disclaimer and Regulatory Notice

This article provides scientific information regarding TB-500 peptide for educational purposes and to assist UK researchers in experimental design. Content is not intended to diagnose, treat, cure, or prevent any disease or medical condition. TB-500 is not approved by the MHRA or EMA for human therapeutic use and is available exclusively as a research chemical for laboratory investigation.

All research protocols cited derive from published preclinical studies and are presented as reference data only—not as recommendations for human application. UK researchers conducting peptide studies bear responsibility for ensuring appropriate institutional approvals, ethical oversight, and regulatory compliance including Home Office licensing where applicable.

Researchers should consult with qualified medical and scientific professionals before designing experimental protocols involving TB-500 or related compounds. Arma Peptides provides research-grade materials for legitimate scientific investigation and does not support, condone, or provide guidance for non-research applications.

TB-500 is prohibited in competitive sports under WADA regulations. Athletes subject to anti-doping testing should not use TB-500 under any circumstances. UK researchers working with athletic populations must implement appropriate safeguards preventing inadvertent anti-doping rule violations.

Product quality specifications, pricing, and availability are subject to change. UK researchers should verify current COA documentation and batch-specific analytical data before incorporating peptides into experimental protocols. For current TB-500 product specifications and batch-specific certificates of analysis, UK researchers may review available options including TB-500 5mg, TB-500 10mg, and BPC-157 + TB-500 Blend formulations.